Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + Docetaxel in Advanced Solid Tumors
NCT02171676Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2005
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 168 days and Incidence and intensity of adverse events up to 35 months. Started May 2005; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02171676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171676.